Abstract
Background and Objectives
Observational studies suggested a bidirectional relationship between Alzheimer’s disease (AD) and epilepsies. However, it remains debated whether and in which direction a causal association exists. The present study aims to explore the relationship between genetic predisposition to AD, CSF biomarkers of AD (Aβ42, pTau) and epilepsies with two-sample, bi-directional Mendelian randomization (MR) method.
Methods
Genetic instruments were obtained from large-scale genome-wide meta-analysis of AD (Ncase/proxy = 111,326, Ncontrol = 677,663), CSF biomarkers of AD (Aβ42 and pTau, N = 13,116) and epilepsy (Ncase = 15,212, Ncontrol = 29,677) of European ancestry. Epilepsy phenotypes included all epilepsy, generalized epilepsy, focal epilepsy, childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, generalized epilepsy with tonic-clonic seizures, focal epilepsy with hippocampal sclerosis, and lesion-negative focal epilepsy. Main analyses were performed using generalized summary data-based mendelian randomization (GSMR). Sensitivity analyses included IVW, MR-PRESSO, MR-Egger, weighted mode, and weighted median.
Results
For forward analysis, genetic predisposition to AD was associated with an increased risk of generalized epilepsy (OR = 1.053, 95% CI: 1.002 ∼ 1.105, P = 0.038), and focal epilepsy with hippocampal sclerosis (OR = 1.013, 95% CI: 1.004∼1.022, P = 0.004). These associations were consistent across sensitivity analyses and replicated using a separate set of instrumental SNPs from another AD GWAS. For reverse analysis, there was a suggestive effect of focal epilepsy with hippocampal sclerosis on AD (OR = 3.994, 95%CI: 1.172∼13.613, P = 0.027). In addition, genetically predicted lower CSF Aβ42 was associated with an increased risk of generalized epilepsy (β = 0.090, 95% CI: 0.022 ∼ 0.158, P = 0.010).
Discussion
The present MR study supports a causal link between AD, amyloid pathology, and generalized epilepsy. This study also indicates a close association between AD and focal epilepsy with hippocampal sclerosis. More effort should be made to screen seizure in AD, unravel its clinical implications, and explore its role as a putative modifiable risk factor.
- Received January 10, 2023.
- Accepted in final form April 3, 2023.
- © 2023 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
